Description
Finasteride and tamsulosin are deliberately combined (as Duodart/Jalyn) for BPH treatment; the combination provides additive symptom relief with no significant adverse pharmacokinetic interaction.
Mechanism
Finasteride reduces prostatic volume by inhibiting 5-alpha-reductase (reducing dihydrotestosterone), while tamsulosin relaxes prostatic smooth muscle by blocking alpha-1A adrenoceptors. The mechanisms are complementary and pharmacologically independent.
Clinical Significance
MTOPS and CombAT trials confirm superior symptom control with combination vs. monotherapy; no clinically significant adverse interaction. Hypotension is not increased beyond tamsulosin's baseline risk.
Management
Standard monitoring for both agents; warn patients about potential first-dose orthostatic hypotension from tamsulosin; monitor PSA (finasteride reduces PSA by ~50% — double observed PSA for interpretation).